Jaguar Health and SynWorld Mutually Terminate License Agreement for Canalevia in Dogs in China

Jaguar Health, Inc.

Jaguar Health (NASDAQ:JAGX) and SynWorld Technologies terminated the exclusive license agreement for Canalevia (crofelemer) to treat diarrhea in dogs in China, effective January 31, 2023.
Termination is driven by Jaguar's 2023 strategic focus on human drug development, including Phase 3 OnTarget trial for cancer therapy-related diarrhea.
SynWorld's General Manager Tao Wang, a long-term shareholder of restricted Jaguar stock, fully supports the mutual termination decision.
All licenses granted to SynWorld under the agreement were revoked, and rights reverted back to Jaguar.
Jaguar expects enrollment in the OnTarget trial to complete in Q2 2023; also prioritizing proof-of-concept trial for short bowel syndrome and congenital diarrheal disorders.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Jaguar Health, Inc. terminated License Agreement with SynWorld Technologies Corporation, C&E Telecom, LTD, and Tao Wang (effective 2023-01-31).

Action: termination
Agreement: license
Counterparty: SynWorld Technologies Corporation, C&E Telecom, LTD, and Tao Wang
Effective: 2023-01-31

Exact text from the filing

On January 31, 2023, the Company, Licensee, C&E Telecom and Wang entered into a Mutual Termination of License Agreement (the “Termination Agreement”), pursuant to which the parties agreed to mutually terminate the License Agreement, effective as of January 31, 2023.

View on SEC.gov

46 material agreements filed in the last 30 days. Browse all material agreements →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-011256

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.